| BACKGROUND
The diagnosis of hypertension-elevated blood pressure (BP) associated with increased cardiovascular disease (CVD) risk-and its management primarily have been based on findings of single daytime office BP measurements (OBPM) assumed to be representative of the systolic (SBP) and diastolic BP (DBP) throughout the 24 hours. 1 OBPM, even when complemented by home BP measurements (HBPM), fail to reveal clinically important features of the mostly predictable 24-hours BP pattern disclosed by comprehensive around-the-clock ambulatory BP monitoring (ABPM). In most diurnally active normotensive and uncomplicated hypertensive persons, this pattern is characterized by the following: (i) striking morning-time rise, (ii) 2 daytime peaksthe first~2-3 hours after awakening and the second early evening, (iii) small midafternoon nadir and (iv) 10%-20% decline (BP dipping) during sleep relative to the wake-time mean, with decline greater for SBP than DBP. 2 Such temporal variation represents the interrelationship of 24 hours cyclic environmental and endogenous determinants. The former include rest-activity rhythm-associated differences in activity routine and level, fluid and stimulant (eg caffeine) consumption, meal timings, content, and size, emotional and mental stress, posture, ambient light intensity and spectrum, weather (temperature and humidity) and noise. The latter include circadian rhythms of neural, endocrine, endothelial, vasoactive peptide and opioid and haemodynamic parameters, for example, plasma noradrenaline and adrenaline, atrial natriuretic and calcitonin gene-related peptides and renin, angiotensin and aldosterone (renin-angiotensin-aldosterone system, RAAS).
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The proper method of determining the features of the 24-hours BP variation, including asleep and awake SBP/ DBP means and dipping pattern, must be based on actual patient bed and rise times rather than the nonrepresentative ones of ABPM propriety software that preassumes common fixed bed and wake times for all patients to generate default "daytime" and "night-time" means. Correctly derived measures of asleep BP and sleep-time relative BP decline (dipping status) by around-the-clock ABPM are important clinical biomarkers of CVD risk. Numerous outcome trials and meta-analyses substantiate correlation between BP level and risk of target organ injury and CVD events is much higher for ABPM-derived parameters, particularly asleep BP, than daytime OBPM. [7] [8] [9] [10] [11] [12] [13] [14] [15] The fall of BP during sleep from its wake-time level is commonly quantified by the sleep-time relative BP decline, that is, per cent decrease in mean BP during sleep relative to the mean BP during wake-time activity. The most common practice is to designate individuals as dippers when the sleep-timerelative SBP decline is ≥10% and as nondippers when <10%; however, the preferred more precise categorization is extreme dippers (decline ≥20%), dippers (decline ≥10%), nondippers (decline <10%) and risers or reverse dippers (decline <0%, ie, asleep SBP mean > awake SBP mean). 1, 16 Although the dipper BP pattern is considered the norm and most common, prevalence of nondipper and riser patterns is very high in certain cohorts, for example, 65%-81% in elderly, 17 type 2 diabetes, 18 chronic kidney disease (CKD) 19 and resistant hypertension patients. 20 This review focuses on (i) asleep BP as the diagnostic feature of hypertension because of its substantiated critical importance along with sleep-time BP decline as the most sensitive predictors of CVD and other health risks and (ii) CVD prevention by targeting control of asleep BP by the simple and low-cost bedtime hypertension chronotherapeutic strategy, that is, judicious scheduling at bedtime of conventional BP-lowering medications. [21] [22] [23] [24] [25] [26] 2 | ASLEEP BP: INDEPENDENT
PROGNOSTIC MARKER OF CVD RISK
ABPM-derived features of the 24-hours BP pattern determined by ABPM have been explored as biomarkers or mediators of target tissue injury and triggers of and risk factors for both CVD-angina pectoris, severe arrhythmias, myocardial infarction, cardiac arrest, heart failure, pulmonary embolism, sudden cardiac death-and cerebrovascular-ischaemic and haemorrhagic stroke-events. 4, 13, [27] [28] [29] Studies consistently verify strong association between blunted sleep-time relative BP decline (nondipper/riser 24-hours BP patterning) and fatal and nonfatal CVD events, not only in hypertensive 8, 10, 13, 28, [30] [31] [32] [33] but also in normotensive individuals. 34 Furthermore, independent prospective investigations demonstrate CVD events are better predicted by the ABPM-ascertained asleep than either awake and 24-hours BP means or daytime OBPM. 10, [13] [14] [15] 28, 32, 33, [35] [36] [37] For instance, Ohkubo et al. 30 in their population-based 9.2-year average follow-up evaluation of the prognostic value of a single baseline 24-hours ABPM found 31% increase in CVD mortality per each 5% reduction in the sleep-time relative SBP decline in hypertensive patients. Of particular, clinical relevance is their finding of no difference in hazard ratio (HR) of CVD mortality between dipper hypertensives (HR = 2.37) and nondipper normotensives (HR = 2.16). 30 viduals with baseline ABPM ranging from normotension to sustained hypertension were prospectively followed up for a median duration of 5.6 years. Hypertensive participants were randomized to two treatment strategies: all prescribed conventional hypertension medications ingested upon awakening or complete daily dose of ≥1 of them ingested at bedtime. At baseline and thereafter annually-or more frequently after doctor-ordered change in therapy either to improve ambulatory BP control or avert sleep-time hypotension utilizing dedicated software for individualized ABPM evaluation 48 -ABPM and wrist actigraphy (to assess physical activity to accurately derive awake and asleep BP means on an individual basis 49 ) were simultaneously carried out for 48 consecutive hours. Registered events included the following: all-cause mortality, myocardial infarction, angina pectoris, coronary revascularization, heart failure, lower-extremity acute arterial occlusion, retinal artery thrombotic occlusion, haemorrhagic and ischaemic stroke and transient ischaemic attack. The primary outcome study endpoint was total CVD morbidity and mortality, which included all the above-listed events.
Cox regression survival analysis of each potential prognostic BP parameter analysed individually-fully adjusted by the significant influential characteristics of sex, age, type 2 diabetes, CKD and hypertension treatment time-indicates the HR of total CVD events is greater with progressively higher asleep SBP mean and lower sleep-time relative SBP decline, that is, more nondipper/riser BP patterning (Figure 1A) . The asleep SBP mean is thus the most significant predictor of total CVD events (per SD increase in asleep SBP mean, HR = 1.51, 95% CI [1.39-1.65], P < .001; Figure 1A) . 13, 28 Moreover, joint analysis of the multiple BP parameters potentially capable of contributing to CVD risk confirms the conclusion of earlier conducted studies 10, 14, 15 that OBPM do not independently predict CVD morbidity and mortality when the outcomes model is adjusted by the asleep BP mean (HR = Figure 1B) . 13, 28 To further investigate the clinical relevance of the asleep BP mean as an independent predictor of CVD risk, the MAPEC study population was divided into four nonoverlapping groups according to BP 2D ; P = .385); and (iii) significantly higher adjusted HR of total CVD events for hypertensive patients with elevated than normal asleep BP mean, whether the awake BP mean is below or above 135/85 mm Hg. Participants of each of the four groups categorized by awake and asleep SBP/DBP means ( Figure 3A ) were further categorized according to either normal or elevated OBPM (using the currently most accepted 140/90 mm Hg thresholds). Results of these analyses shown in Figure 3B denote CVD risk is significantly higher in all of the four patient cohorts classified as having elevated asleep BP mean, regardless of whether the daytime OBPM or ABPM-derived awake BP mean is normal or elevated, than in all of the other four cohorts classified as having normal sleep-time BP mean. In summary, the asleep BP mean, but not the OBPM or ABPM-obtained awake BP mean, is the most significant and independent prognostic marker of CVD morbidity and mortality. 13, 28 We additionally investigated the joint association of elevated asleep BP mean and blunted sleep-time relative BP decline with increased CVD risk ( Figure 1B) . Accordingly, participants of the MAPEC study were further divided into four nonoverlapping groups according to 120/70 mm Hg thresholds for asleep SBP/DBP means and arbitrary ≥10% (dipper BP pattern) or <10% (nondipper BP pattern) threshold for sleep-time relative SBP decline. Results shown in Figure 4 
| ASLEEP BP: THERAPEUTIC TARGET FOR CVD RISK REDUCTION
Unlike other ABPM-based investigations, the MAPEC study was designed to permit prospective evaluation of the impact of changes in both OBPM and ABPM during follow-up on CVD risk by incorporating multiple periodic (at least annual) 48-hours ABPM assessments. Progressive treatment-induced lowering of the awake, asleep and 48-hours BP means, but not daytime OBPM, when each variable is analysed individually (Figure 5A ), reveals association with significant CVD risk reduction. Change during follow-up in morning BP surge is not significantly associated with CVD risk modification; however, as depicted in Figure 5A , progressive increase during follow-up in sleep-time relative SBP decline towards normal dipper patterning is significantly associated with increased event-free survival. Most importantly, Cox survival analysis with joint inclusion of asleep and awake BP means as potential predictors indicates, as shown in Figure 3B, Figure 5B ). Figure 6A presents for the entire MAPEC patient population categorized into quintiles the relationship between CVD risk and achieved asleep SBP mean at the final ABPM evaluation per participant, that is, either before a documented CVD event in event subjects or latest assessment in nonevent individuals. Treatment-induced reduction in asleep SBP mean across all quintiles is associated with highly significant attenuation of CVD risk. Indeed, CVD risk is lowest when the achieved asleep SBP mean is <100.3 mm Hg, with average asleep SBP mean for individuals of this first quintile being 93.8 AE 5.8 mm Hg. The relationship between the adjusted HR of total CVD events and achieved awake SBP mean at the final evaluation per participant for the respective quintiles is displayed in Figure 6B . The HR was only slightly, but not significantly, larger in the last two compared to the first three quintiles, that is, when the attained awake SBP mean is >126 mm Hg. , a-blockers, ß-blockers and diuretics-and their combinations are greatly improved when routinely ingested at bedtime than upon awakening as customary. [21] [22] [23] [24] [25] [26] 50, 51 For example, because the highamplitude circadian rhythm of the RAAS activates during sleep, 6 bedtime vs morning dosing of conventional longacting ACEI and ARB medications reduces in much greater extent the asleep than awake BP means, with additional benefit independent of drug terminal half-life of converting abnormal nondipper 24-hours BP patterning into the more normal dipper one. 23, 24 This section based on findings of longitudinal outcomes trials addresses whether the bedtime hypertension treatment strategy, which better normalizes the sleep-time BP and sleep-time relative BP decline than the upon-awakening one, is also more protective against CVD events than customary morning-time one. The Heart Outcomes Prevention Evaluation (HOPE) trial examined the relevance of adding the ACEI ramipril at bedtime vs placebo to an already existing BP-lowering, cholesterol-reducing and other preventive interventions for reducing CVD and stroke events in 9297 high-risk CVD patients ≥55 years of age. 52 The Syst-Eur and Syst-China CVD outcome trials investigated the impact of dihydropyridine CCB nitrendipine vs placebo evening therapy on stroke incidents and other CVD complications in elderly patients with isolated systolic hypertension diagnosed solely on the basis of daytime OBPM. 53, 54 The controlled- and awake SBP mean (Panel B) at the final evaluation per participant, either before the documented CVD event in event subjects or latest assessment in nonevent individuals. The studied population was divided into five classes of equal size (quintiles). Adjustments were applied for the same variables as in Figure 1 onset extended-release (COER) verapamil investigation of cardiovascular endpoints (CONVINCE) trial explored whether initial treatment with 180 mg of the unique COER verapamil medication, specially formulated for bedtime ingestion to achieve peak serum drug concentration upon morning arising and initial hours of the diurnal activity span when BP is assumed in all patients to rapidly rise from its reduced sleep-time level and trigger angina pectoris and myocardial infarct, is equivalent to morning treatment with either 50 mg of the ß-agonist atenolol or 12.5 mg of the diuretic hydrochlorothiazide in preventing as primary outcomes myocardial infarction, stroke and CVD death. 55 ABPM studies reveal bedtime ingestion of COER verapamil, however, significantly reduces morning BP, but exerts only limited effect on asleep BP. 56 These listed evening therapy investigations lacked a comparator morning (upon awakening) treatment-time arm of the same trialled medications; thus, they cannot be considered proper chronotherapy outcome trials. Nonetheless, it is of interest that Roush et al., 57 who compared the results of the above-summarized studies in which the tested active hypertension medications were always ingested in the evening/bedtime with those of 147 clinical trials of an earlier meta-analysis in which hypertension medications were always ingested in the morning, 58 found significant 48% enhanced attenuation (P = .008) of the relative risk of CVD events with the evening/bedtime vs morning therapeutic approach. 57 We wish to emphasize the MAPEC study is the first completed-as-designed prospective trial to specifically test the hypothesis bedtime hypertension chronotherapy with major treatment goals attenuation of asleep BP mean, and enhancement of sleep-time relative BP decline better reduces CVD and stroke risk than conventional morningtime therapy with major treatment goal attenuation of daytime BP. 13, [40] [41] [42] [43] [44] [45] [46] After a median follow-up of 5.6 years, hypertensive participants randomized to ingest the full daily dose of ≥1 BP-lowering medications at bedtime, vs those randomized to ingest all prescribed hypertension medications upon awakening, displayed as expected-based upon the many previously conducted morning vs bedtime treatment-time investigations [21] [22] [23] [24] [25] [26] 50, 51 -significantly lower asleep BP mean, higher sleep-time relative BP decline, lesser prevalence of nondipping (34 vs 62%; P < .001) and higher prevalence of properly controlled ambulatory BP (62 vs 53%, P < .001). Most importantly, bedtime, compared to upon-awakening, therapy resulted in significantly lower adjusted HR of total (HR = 0.39 95% CI [0.29-0.51]; P < .001) and major CVD events-composite of CVD death, myocardial infarction and ischaemic and haemorrhagic stroke (HR = 0.33 [0.19-0.55]; P < .001). 40 The MAPEC study not only substantiates the asleep SBP mean is the most significant independent ABPMderived prognostic marker of CVD morbidity and mortality 13, 28 as earlier discussed, a finding also corroborated in several other prospective ABPM studies, 10 
| CONCLUSIONS
Current hypertension diagnostic methods and treatment strategies that dominate clinical practice are anchored in the past, unfortunately disregarding the value of ABPM and now well-established facts derived from ABPM-based hypertension outcome trials, in particular, correlation between BP and CVD risk is far stronger for the asleep SBP mean and sleep-time relative SBP decline than daytime OBPM. 10, [13] [14] [15] 28, 32, 33, [35] [36] [37] On the basis of the substantial and indisputable evidence of significantly better prognostic value of these around-the-clock ABPM-derived endpoints, several international guidelines propose ABPM be conducted as requirement to confirm OBPM-based diagnosis of hypertension in adults. 63, 64 However, compliance with these recommendations has been slow and, furthermore, there is no consensus as yet of the exact ABPM parameter that should be used for clinical decisions. The latest update of the British guidelines for clinical management of adult primary hypertension from the National Institute for Health and Clinical Excellence (NICE) specifies use of "the average of at least 14 measurements taken during the person's usual waking hours to confirm a diagnosis of hypertension". The NICE guidelines by explicitly recommending clinical decisions be based solely upon the ABPM-derived daytime SBP/DBP means ≥135/85 mm Hg -the established wake-time thresholds for adults 1 regardless of sex and presence of compelling clinical conditions of type 2 diabetes, CKD and past history of CVD events associated with highest CDV risk 16 -disregards the persuasive findings of numerous investigations 10, [13] [14] [15] 28, 32, 33, [35] [36] [37] that document asleep BP more strongly predicts future CVD events than does wake-time ambulatory BP. Furthermore, the NICE guidelines ignore the considerable prevalence and adverse implications of masked hypertension, that is, normal office BP but elevated ambulatory BP, and "nondipping normotension", that is, the absence of sleep-time relative decline from the daytime BP mean level by ≥10% in individuals with otherwise normal ambulatory BP levels. 34 Guidelines of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) state "it is now generally accepted that out-of-office BP is an important adjunct to conventional OBPM, but the latter currently remains the 'gold standard' for screening, diagnosis and management of hypertension". 1 On the basis of current evidence presented herein establishing the prognostic value of asleep BP, the present ESH/ESC guidelines seem not only outdated but also clinically inappropriate by advocating the "time-honoured value" of OBPM over much more comprehensive and representative around-the-clock ABPM.
The recent 2015 U.S. Preventive Services Task Force (USPSTF) report 64 recommends ABPM be the preferred means of making the differential diagnosis of hypertension vs normotension and predicting CVD risk. Its most important conclusions are as follows 64 : (i) parameters obtained from around-the-clock ABPM best predict long-term adverse CVD outcomes and independently of daytime OBPM; and (ii) around-the-clock ABPM, rather than traditional daytime OBPM, should now be considered the reference standard in primary care medicine to diagnose hypertension in adults ≥18 years of age. Thus, the USPSTF report advocates application of ABPM either to corroborate or contradict daytime OBPM-diagnosed elevated BP to avoid misdiagnosis and unnecessary treatment of persons who display elevated OBPM but proven normotensive by ABPM-commonly termed isolated office hypertension, although the more accurate and preferred term is masked normotension. 16 On the basis of an exploratory meta-analysis of no apparent difference in HR for CVD risk per 10 mm Hg increase between the ABPM-derived night-time, daytime and 24-hours SBP means, the USPSTF report concludes anyone of those mean values might be used interchangeably to corroborate diagnosis of hypertension in adults. 64 However, this conclusion is questionable because of large differences between consulted studies as to how "night-time" and "daytime" were defined plus absence of emphasis on the most clinically meaningful endpoint of asleep BP mean, the strongest independent predictor of future CVD events. 39 The 2017 joint report of the American College of Cardiology (ACC) and the American Heart Association (AHA) updates guidelines for prevention, detection, evaluation and management of high BP in adults. 65 Similarly to the ESH/ ESC recommendations, 1 the ACC/AHA guidelines rely on OBPM to define hypertension, although establishing lower values of 130/80 mm Hg for clinic SBP/DBP as new diagnostic thresholds and therapeutic targets, regardless of age, sex and the presence/absence of comorbidities, including diabetes, CKD and previous CVD event. 65 Using as reference the above-discussed USPSTF report, 64 the ACC/AHA guidelines state "out-of-office measurement of BP can be helpful for confirmation and management of hypertension". Specifically, the ACC/AHA report addresses the importance of identifying persons with masked normotension and masked hypertension; however, these two categories are misleadingly defined by comparing OBPM with daytime ABPM and HBPM, thus totally disregarding, once again, asleep BP as the strongest independent prognosticator of CVD risk, leading to misclassification of persons with true masked normotension or masked hypertension. 66 Furthermore, these as do other guidelines that focus primarily on findings of previously conducted OBPM outcome trials over ABPM ones that substantiate greater relevance of sleep-time than wake-time BP lead to incomplete and even incorrect conceptualization and definition of hypertension and thus less than optimal treatment strategies required to attain truly meaningful attenuation of associated health risks.
The findings of the MAPEC study entailing systematic periodic 48-hours ABPM evaluation of participants during a median follow-up of 5.6 years constitute the first proofof-concept evidence the progressive reduction in the asleep SBP mean, and correction of the sleep-time relative SBP decline towards normal best attenuates the risk of CVD, stroke, new-onset diabetes and CKD. 13, [40] [41] [42] [43] [44] [45] [46] Results of this study further corroborate the clinical objectives of superior BP control plus greater CVD risk reduction can be accomplished easily without additional cost through a hypertension treatment strategy that entails ingestion ≥1 conventional BP-lowering medications at bedtime in step with key physiologic, neuroendocrine, endothelial and other circadian rhythms that regulate the 24-hours BP pattern and its features. [4] [5] [6] Despite these multiple factors influencing the mostly predictable circadian BP variation and the sleep-BP level, the impact of hypertension treatment time on asleep BP regulation might thus be clinically relevant not only for CVD risk reduction, as previously documented, [40] [41] [42] but also for preventing new-onset diabetes 44 and development of CKD. 46 In particular, the bedtime, in comparison with awakening, ingestion schedule of ARB and ACEI medications, irrespective of their terminal half-life, results in greater therapeutic effect on asleep BP. [23] [24] [25] [26] Accordingly, blocking the circadian rhythm-dependent overnight rise in RAAS activity by bedtime ARB and ACEI therapies seems to be a cost-efficient means of normalizing elevated asleep BP mean and attenuated sleeptime relative BP decline. Interestingly, antagonism of the RAAS by reduction in angiotensin II formation and blockade of its receptors achieved either by a bedtime ACEI or ARB ingestion strategy has been documented to be superior to any other treatment scheme for reducing CVD, 67 diabetes 44 and CKD 46 risks.
Additional prospective long-term outcomes trials that incorporate periodic ABPM assessments and simultaneous diary recording of bed and wake times to accurately and reliably ascertain asleep and wake-time BP level and dipping status-as done in the completed MAPEC study and ongoing much larger Hygia Project [18] [19] [20] 68 -are needed to confirm the highly significant independent prognostic value of sleep-time BP plus beneficial effects (reduced risk of CVD events and target tissue and organ injury) and safety of enhanced asleep BP reduction by bedtime hypertension chronotherapy.
